Group 1 - Danaher Corporation's Board of Directors has approved a quarterly cash dividend of $0.32 per share, reflecting an 18.5% increase from the previous dividend of $0.27 [1] - The dividend is payable on April 25, 2025, to shareholders of record on March 28, 2025 [1] Group 2 - Danaher is a leading global innovator in life sciences and diagnostics, focused on improving human health through science and technology [2] - The company collaborates with customers to address significant health challenges, enabling faster and more accurate diagnoses [2] - Danaher's workforce of approximately 63,000 associates is dedicated to enhancing quality of life and establishing a sustainable future [2]

Core Viewpoint - Danaher Corp. has experienced a market decline following the release of its annual results on January 29, as evidenced by a noticeable drop in "total return" and "drawdown" charts since that date [1]. Company Analysis - Danaher Corp. is categorized as a company that aims to identify the best businesses globally to build a long-term portfolio that can outperform the market [1].

Core Insights - Danaher Corporation's fourth-quarter 2024 adjusted earnings per share were $2.14, missing the Zacks Consensus Estimate of $2.17, but reflecting a year-over-year increase of 2.4% [1] - The company reported net sales of $6.5 billion, exceeding the consensus estimate of $6.4 billion, with a year-over-year increase of 2.1% driven by strong performance in the Diagnostics and Life Sciences segments [2] Segment Performance - Life Sciences segment revenues reached $2.03 billion, up 5.5% year over year, with core sales increasing by 1% and operating profit rising 60% to $376 million [3] - Diagnostics segment revenues totaled $2.64 billion, down 3% year over year, with core sales decreasing by 2% and operating profit declining 18.5% to $624 million [4] - Biotechnology segment revenues were $1.87 billion, up 6.5% year over year, with core sales increasing by 8% and adjusted operating profit rising 22.1% to $508 million [5] Financial Metrics - Danaher's cost of sales increased by 0.8% year over year to $2.6 billion, while gross profit rose 3.8% to $3.4 billion, resulting in a gross margin of 59.5% [6] - Operating profit increased by 6.6% year over year to $1.43 billion, although the operating margin contracted to 21.8% from 20.9% [7] Balance Sheet and Cash Flow - At the end of the fourth quarter, Danaher had cash and equivalents of $2.1 billion, down from $5.9 billion at the end of 2023, while long-term debt decreased to $15.5 billion from $16.7 billion [8] - The company generated net cash of $6.68 billion from operating activities, up from $6.49 billion in the previous year, with adjusted free cash flow increasing 3.5% year over year to $5.31 billion [9] Outlook - For the first quarter, Danaher anticipates adjusted core sales from continuing operations to decline in low-single digits year over year, with an expected increase of approximately 3% year over year in 2025 [10]

Core Insights - Danaher reported $6.54 billion in revenue for Q4 2024, a year-over-year increase of 2.1% and a surprise of +1.22% over the Zacks Consensus Estimate of $6.46 billion [1] - The EPS for the quarter was $2.14, slightly below the consensus estimate of $2.17, resulting in an EPS surprise of -1.38% [1] Financial Performance Metrics - Organic sales growth was 1%, outperforming the four-analyst average estimate of -1.1% [4] - Total sales in Diagnostics reached $2.64 billion, exceeding the average estimate of $2.56 billion, but reflecting a year-over-year decline of -2.9% [4] - Life Sciences sales totaled $2.03 billion, surpassing the average estimate of $1.97 billion, with a year-over-year increase of +5.3% [4] - Biotechnology sales were reported at $1.87 billion, matching the average estimate, and showing a year-over-year growth of +6.3% [4] Operating Profit Analysis - Operating profit in Life Sciences was $376 million, exceeding the average estimate of $294.50 million [4] - Operating profit in Biotechnology was $508 million, slightly below the average estimate of $516.79 million [4] - Diagnostics operating profit was $624 million, compared to the average estimate of $792.33 million, indicating a significant shortfall [4] - Other operating profit was reported at -$83 million, worse than the average estimate of -$77.29 million [4] Stock Performance - Danaher's shares returned +8% over the past month, outperforming the Zacks S&P 500 composite's +1.7% change [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance in the near term [3]

Danaher Corporation Fourth Quarter 2024 Earnings Release January 29, 2025 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward- looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those ...

分组1 - Danaher reported quarterly earnings of $2.14 per share, missing the Zacks Consensus Estimate of $2.17 per share, but showing an increase from $2.09 per share a year ago, resulting in an earnings surprise of -1.38% [1] - The company posted revenues of $6.54 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.22% and showing an increase from $6.41 billion year-over-year [2] - Danaher has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has gained about 8% since the beginning of the year, outperforming the S&P 500's gain of 3.2% [3] - The current consensus EPS estimate for the coming quarter is $1.98 on revenues of $5.99 billion, and for the current fiscal year, it is $8.18 on revenues of $24.62 billion [7] - The Zacks Industry Rank indicates that the Diversified Operations sector is currently in the bottom 27% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8]

Core Insights - Danaher Corporation reported strong fourth quarter and full year results for 2024, with core revenue exceeding expectations across all segments [2][9] - The company is positioned for higher long-term growth, expanded margins, and stronger cash flow due to its focused transformation in life sciences and diagnostics [2][3] Key Fourth Quarter 2024 Results - Net earnings were $1.1 billion, or $1.49 per diluted common share, with non-GAAP adjusted diluted net earnings per common share at $2.14 [9] - Revenues increased by 2.0% year-over-year to $6.5 billion, while non-GAAP core revenue rose by 1.0% [9] - Operating cash flow was $2.0 billion, and non-GAAP free cash flow was $1.5 billion [9] Key Full Year 2024 Results - Net earnings totaled $3.9 billion, or $5.29 per diluted common share, with non-GAAP adjusted diluted net earnings per common share at $7.48 [9] - Revenues were flat year-over-year at $23.9 billion, with non-GAAP core revenue decreasing by 1.5% [9] - Operating cash flow reached $6.7 billion, and non-GAAP free cash flow was $5.3 billion [9] First Quarter and Full Year 2025 Outlook - For Q1 2025, the company anticipates a low-single-digit decline in non-GAAP core revenue year-over-year [3] - For the full year 2025, a projected increase of approximately 3% in non-GAAP core revenue is expected [3] Segment Performance - Total sales growth for the fourth quarter was 2.0%, with biotechnology segment growth at 6.5%, life sciences at 5.5%, and diagnostics declining by 3.0% [19] - For the full year, total sales growth was flat, with biotechnology down 6.0%, life sciences up 2.5%, and diagnostics up 2.0% [21] Cash Flow and Financial Position - Total cash provided by operating activities for Q4 2024 was $2.0 billion, a 27.0% increase from Q4 2023 [24] - Free cash flow from continuing operations for Q4 2024 was $1.5 billion, a 29.5% increase from the previous year [24] Balance Sheet Highlights - As of December 31, 2024, total assets were $77.5 billion, down from $84.5 billion in 2023 [31] - Current liabilities decreased to $6.8 billion from $8.3 billion in the previous year [31] - Stockholders' equity was $49.5 billion, down from $53.5 billion in 2023 [31]

Financial Performance Presentation - Danaher Corporation will present estimated financial performance for Q4 2024 at the J.P. Morgan Healthcare Conference on January 14, 2025[9] - The presentation slides include key financial performance estimates for 2024[9] - The financial performance details are furnished pursuant to Item 2.02 of Form 8-K[9] - The financial performance estimates are part of the company's public webcast presentation[9] Exhibits and Attachments - The press release titled "Danaher CEO to Comment on Financial Performance" is attached as Exhibit 99.1[10] - Selected Danaher Presentation Slides for the J.P. Morgan Healthcare Conference are attached as Exhibit 99.1PRE[10] - The filing includes an Interactive Data File (XBRL) as Exhibit 104[10] Form 8-K Filing Details - The presentation slides and press release are incorporated by reference in the Form 8-K filing[9] - The filing is dated January 13, 2025, and relates to the company's financial condition and operations[9][12] - The report is signed by Matthew R. McGrew, Executive Vice President and Chief Financial Officer[12]

Core Viewpoint - Danaher Corporation is expected to report its fourth-quarter 2024 results on January 29, with mixed expectations regarding revenue and earnings growth [1][2]. Revenue and Earnings Estimates - The Zacks Consensus Estimate for revenues is $6.44 billion, reflecting a 0.5% increase year-over-year [2]. - The consensus estimate for earnings is $2.16 per share, indicating a 3.4% increase from the previous year [2]. - The company has a trailing four-quarter earnings surprise average of 10.2% [2]. Segment Performance - Weakness in the Instrument businesses, particularly in the Life Sciences segment, is anticipated due to lower demand in the pharma and biotech markets in China, with organic revenues expected to decline by 2.6% year-over-year [4]. - The Biotechnology segment is also expected to be negatively impacted by decreased demand in the discovery and medical business [5]. - The Diagnostics segment is expected to show strength, driven by growth in Leica Biosystems and Beckman Colter Diagnostics units [6]. Expenses and Profitability - SG&A expenses are projected to be $2.1 billion, representing a 3.2% increase year-over-year, which may affect the bottom line [5]. - Foreign currency headwinds are likely to impact profitability due to the company's significant international operations [5]. Recent Developments - Danaher acquired Abcam plc in December 2023, which is expected to enhance the Life Sciences segment and address healthcare challenges [7]. Earnings Prediction Insights - The company has an Earnings ESP of +0.96%, with the Most Accurate Estimate at $2.18 per share, slightly above the Zacks Consensus Estimate [9]. - Danaher currently holds a Zacks Rank of 4 (Sell), indicating a lower likelihood of an earnings beat this quarter [9].

Core Viewpoint - Danaher (DHR) is anticipated to report a year-over-year increase in earnings and revenues for the quarter ended December 2024, with earnings expected to be $2.16 per share, reflecting a +3.4% change, and revenues projected at $6.41 billion, up 0.1% from the previous year [1][3]. Earnings Expectations - The stock may experience upward movement if the earnings report exceeds expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 1.41% lower over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP reading indicates a likely earnings beat, particularly when combined with a strong Zacks Rank [8]. - For Danaher, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1.40% [10][11]. Historical Performance - Danaher has a history of beating consensus EPS estimates, having done so in the last four quarters, including a +9.62% surprise in the last reported quarter [12][13]. Investment Considerations - Despite the positive earnings outlook, Danaher currently holds a Zacks Rank of 4, complicating predictions of an earnings beat [11][16]. - Investors are advised to consider other factors beyond earnings surprises when making investment decisions regarding Danaher [14][15].